QuiaPEG Pharmaceuticals Holding AB (QUIA) AI Stock Analysis

• Market Cap: €8.28M
• Dividend Yield: N/A
• Average Volume (3M): 21.55M
• Price to Earnings (P/E): ―
• Beta (1Y): -3.07
• Revenue Growth: -100.00%
• EPS Growth: 50.33%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 2,124,285,000
• 10 Day Avg. Volume: 10,784,979
• 30 Day Avg. Volume: 21,553,206
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

QuiaPEG Pharmaceuticals' overall score is impacted significantly by its financial performance, with zero revenue and ongoing losses posing substantial risks. The lack of technical indicators and negative valuation metrics further weigh on the stock's attractiveness. Despite some balance sheet improvements, the company's operational challenges and reliance on external financing are key concerns.

QuiaPEG Pharmaceuticals Holding AB Business Overview & Revenue Model

Company Description

QuiaPEG Pharmaceuticals Holding AB (QUIA) is a Swedish biotechnology company focused on developing and commercializing advanced drug delivery systems. The company specializes in the PEGylation of pharmaceuticals, which involves attaching polyethylene glycol (PEG) polymers to drugs to enhance their therapeutic properties. This technology is aimed at improving drug stability, solubility, and half-life, thereby optimizing the efficacy of various treatments. QuiaPEG's core products are centered around its proprietary Uni-Qleaver technology platform, which is designed to facilitate controlled release and targeted delivery of pharmaceutical compounds.

How the Company Makes Money

QuiaPEG Pharmaceuticals Holding AB generates revenue primarily through the licensing of its proprietary drug delivery technologies to pharmaceutical companies. The company enters into collaborative agreements with other biotech and pharmaceutical firms, allowing them to utilize QuiaPEG's PEGylation technology in the development of their own drug compounds. Revenue streams include upfront payments, milestone payments, and royalties on sales of successfully commercialized products using its technology. Additionally, QuiaPEG may engage in co-development partnerships, sharing both the risks and rewards of bringing new drugs to market. Strategic alliances and partnerships play a significant role in the company's earnings, leveraging the expertise and distribution networks of larger pharmaceutical entities to expand the reach and impact of its technology.

QuiaPEG Pharmaceuticals Holding AB Financial Statement Overview

Summary

QuiaPEG Pharmaceuticals is facing considerable financial challenges, characterized by zero revenue, significant losses, and a reliance on external financing. Despite improvements in equity and reduction in liabilities, the company's operational and cash flow performance require substantial enhancement to ensure long-term sustainability.

Income Statement

QuiaPEG Pharmaceuticals has experienced significant revenue volatility, with revenue dropping to zero in the latest year. The gross profit margin is not applicable due to the absence of revenue, and the company continues to face substantial losses with negative EBIT and net income, indicating ongoing operational challenges.

Balance Sheet

The company's balance sheet shows a reduction in total assets and liabilities, with stockholders' equity improving compared to past deficits. The absence of debt this year is a positive sign, but the overall equity position remains weak relative to total assets, which could limit financial flexibility.

Cash Flow

QuiaPEG's cash flow statement reveals a continued reliance on financing to cover operating losses. The negative free cash flow indicates operational inefficiencies, although the decrease in free cash flow deficit over the period suggests incremental improvements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.99M	0.00	4.37M	5.57M	216.00K	1.86M
Gross Profit	3.69M	460.00K	2.17M	8.91M	527.00K	-2.99M
EBITDA	-11.45M	-9.71M	-13.43M	-13.98M	-16.01M	-23.67M
Net Income	-13.86M	-28.93M	-16.52M	-24.38M	-22.43M	-30.49M
Balance Sheet
Total Assets	42.57M	22.75M	41.96M	23.44M	23.76M	20.54M
Cash, Cash Equivalents and Short-Term Investments	2.58M	2.00K	101.00K	2.57M	5.34M	8.59M
Total Debt	3.33M	0.00	20.61M	15.52M	17.80M	15.75M
Total Liabilities	7.89M	6.39M	26.71M	21.03M	23.74M	20.47M
Stockholders Equity	34.68M	16.35M	15.25M	2.41M	22.00K	71.00K
Cash Flow
Free Cash Flow	-6.86M	-10.63M	-34.64M	-23.75M	-28.70M	-30.81M
Operating Cash Flow	-6.86M	-10.17M	-10.27M	-18.18M	-20.11M	-28.31M
Investing Cash Flow	-22.63M	-460.00K	-24.37M	-5.57M	-8.59M	-2.50M
Financing Cash Flow	28.68M	10.53M	32.17M	20.98M	25.46M	34.86M

QuiaPEG Pharmaceuticals Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LARK	52 Neutral	44.95M	-0.99	0.00%	8.81%	-94.12%	-25.83%
EXPRS2	41 Neutral	45.78M	-0.85	-55.62%	―	-13.08%	32.78%
QUIA	32 Underperform	€8.28M	―	-135.41%	―	-100.00%	50.33%
SCOL	30 Underperform	3.00M	-0.03	-443.37%	―	0.00%	57.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%